BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11858029)

  • 1. [Clinical experience with positron emission tomography with 2-fluorine, 18F-2-deoxy-d-glucose used for the diagnosis of malignant breast neoplasms].
    Tiutin L; Fadeev N; Ryzhkova D; Kostenikiv N; Arzumanov A; Savello V; Tlostanova M
    Vestn Rentgenol Radiol; 2001; (6):14-8. PubMed ID: 11858029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer.
    van der Hoeven JJ; Krak NC; Hoekstra OS; Comans EF; Boom RP; van Geldere D; Meijer S; van der Wall E; Buter J; Pinedo HM; Teule GJ; Lammertsma AA
    J Clin Oncol; 2004 Apr; 22(7):1253-9. PubMed ID: 15051773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
    Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
    J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
    J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.
    Mahner S; Schirrmacher S; Brenner W; Jenicke L; Habermann CR; Avril N; Dose-Schwarz J
    Ann Oncol; 2008 Jul; 19(7):1249-1254. PubMed ID: 18356138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
    Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
    J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma.
    Port ER; Yeung H; Gonen M; Liberman L; Caravelli J; Borgen P; Larson S
    Ann Surg Oncol; 2006 May; 13(5):677-84. PubMed ID: 16538409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
    Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
    J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET imaging in breast cancer.
    Bombardieri E; Crippa F
    Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography.
    Pecking AP; Mechelany-Corone C; Bertrand-Kermorgant F; Alberini JL; Floiras JL; Goupil A; Pichon MF
    Clin Breast Cancer; 2001 Oct; 2(3):229-34. PubMed ID: 11899417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
    Bender H; Kirst J; Palmedo H; Schomburg A; Wagner U; Ruhlmann J; Biersack HJ
    Anticancer Res; 1997; 17(3B):1687-92. PubMed ID: 9179219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet!
    Guller U; Nitzsche EU; Schirp U; Viehl CT; Torhorst J; Moch H; Langer I; Marti WR; Oertli D; Harder F; Zuber M
    Breast Cancer Res Treat; 2002 Jan; 71(2):171-3. PubMed ID: 11881913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
    Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
    Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience.
    Hathaway PB; Mankoff DA; Maravilla KR; Austin-Seymour MM; Ellis GK; Gralow JR; Cortese AA; Hayes CE; Moe RE
    Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
    Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
    Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET.
    Eubank WB; Mankoff DA; Vesselle HJ; Eary JF; Schubert EK; Dunnwald LK; Lindsley SK; Gralow JR; Austin-Seymour MM; Ellis GK; Livingston RB
    Radiographics; 2002; 22(1):5-17. PubMed ID: 11796893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.